SEC Form 4 · accession 0001209191-18-030056
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura Clague
Officer — Chief Financial Officer
Period of report
May 10, 2018
Accepted (ET)
May 14, 2018 · 7:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 10, 2018 | A | 10,000 | $0.00 | A | 12,033 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee stock option (right to buy)F1 | $25.25 | May 10, 2018 | A | 48,000 | A | — | May 9, 2028 | Common Stock | 48,000 | 48,000 | D |
| Performance-based restricted stock unitsF2,F3 | — | May 10, 2018 | A | 8,000 | A | — | — | Common Stock | 8,000 | 8,000 | D |
Explanation of responses
- F1One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
- F2Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
- F3This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date.